Acetyl hexapeptide-38 is a cosmetic peptide associated with Adifyline, an ingredient marketed for facial and body volume. The important qualification is that a supplier’s proposed mechanism and study summaries do not establish that every cream containing it will restore facial fat or produce lasting breast enlargement.
There is some human testing described in supplier materials, so calling the evidence entirely laboratory-based would also be misleading. The useful question is what was tested, how the result was measured, and whether the findings apply to the product you are considering.
What is acetyl hexapeptide-38?
A peptide is a short chain of amino acids; hexapeptide means that the chain contains six. The PubChem record for Adifyline identifies a six-amino-acid sequence and lists Acetyl Hexapeptide-38 among its synonyms. The number 38 identifies this particular ingredient; it does not describe its strength or rank it against other peptides.
In a cosmetic ingredient list, look for Acetyl Hexapeptide-38, the INCI name. INCI stands for International Nomenclature of Cosmetic Ingredients, the naming system used for cosmetic ingredients.
Adifyline is the commercial ingredient name you may encounter in marketing. Iwase Cosfa’s official ingredient page lists the supplied material as Butylene Glycol, Water, Acetyl Hexapeptide-38 and names Lubrizol as the supplier. That distinction matters: a peptide solution, the peptide molecule, and a finished moisturizer are different things.
An advertised percentage of a branded solution should not automatically be read as the same percentage of pure peptide. Ask what the percentage refers to before comparing two claims.
Why is Adifyline marketed for volume?
The proposed mechanism involves adipogenesis, the process through which precursor cells develop into fat cells. Lubrizol’s product listing on its Knowde storefront describes stimulation of PGC-1α expression and increased lipid accumulation. PGC-1α is a transcriptional coactivator: a protein that helps regulate gene activity, including through interaction with PPARγ in the supplier’s explanation of fat-cell development.
This is the supplier’s biological rationale for the ingredient’s volume claims. It should be read as a proposed route to an effect, rather than a prediction of what will happen to your face.
For a topical volume claim, several questions still need answers: does the finished formula deliver the ingredient to the relevant tissue, does a controlled study show a meaningful change, and does that change persist? A mechanism alone cannot answer those questions.
What does the evidence actually show?
The publicly accessible materials reviewed on September 18, 2026 provide different kinds of information. They should not be treated as interchangeable proof.
| Material | What it contributes | What it cannot establish by itself |
|---|---|---|
| Supplier mechanism description | A rationale involving fat-cell development and lipid storage | The amount of visible change from a retail cream |
| Official distributor’s human-study summary | A description of topical testing with a placebo comparison | Full independent verification of the result or its durability |
| An ingredient identity record | Confirmation of the substance’s name and identifiers | Clinical efficacy or regulatory approval |
| Evidence for a particular finished formula, if provided | Findings relevant to that tested formula and endpoint | The peptide’s isolated contribution without an appropriate comparison |
A human-study summary exists, but important details remain unavailable
Iwase Cosfa describes a study involving 22 women aged 25–45 over 56 days. One breast received a cream containing the Adifyline solution, while the other received a placebo cream. The page describes volume measurements at several time points and also mentions cheek-volume testing.
A comparison with placebo is more informative than an uncontrolled before-and-after photograph. However, the accessible page is a commercial summary. I could not verify the full protocol, participant-level results, randomization and blinding procedures, statistical analysis, adverse-event reporting, or follow-up after treatment stopped. The summary therefore supports saying that human testing was reported; it does not support a confident prediction of lasting enlargement.
A medical case report does not validate an ordinary topical cream
A 2026 case-report abstract indexed in PubMed describes acetyl hexapeptide-38 as one part of a combined intervention for chronic peripheral facial paralysis. It combines a procedure with multiple substances, rather than isolating a consumer cream or this peptide alone.
Only the indexed abstract was accessible for this review. It is insufficient to attribute any reported outcome specifically to acetyl hexapeptide-38 or to extrapolate the intervention to everyday skincare.
Targeted searches for “acetyl hexapeptide-38” and “Adifyline” did not yield an accessible independent controlled trial of a topical consumer product that I could verify for this article. This is a limitation of the review, not proof that no such research exists.
Can it increase breast size or replace fillers?
The reviewed evidence does not justify expecting reliable, lasting breast enlargement from a product simply because it contains acetyl hexapeptide-38. The distributor’s study summary is relevant to the question, but leaves substantial uncertainty about the result’s magnitude, reproducibility, and persistence.
Likewise, it does not establish that a topical cream produces results equivalent to an injectable filler. Such a comparison would need evidence that directly assesses comparable outcomes. “Volume,” “plumping,” and “filler-like” are not interchangeable measurements.
When you read a dramatic multiplier such as “many times greater than placebo,” look for the absolute changes in both groups. A ratio alone does not tell you whether the difference would be noticeable or meaningful to you. Also ask whether the measurement reflects surface shape, tissue volume, or another endpoint; a measured contour change should not automatically be described as confirmed growth of underlying fat tissue.
How to evaluate a product claim
Before paying a premium for the ingredient, look for information about the finished product, rather than relying only on a raw-material brochure:
- Current ingredient list: does the actual product list Acetyl Hexapeptide-38?
- Study attribution: was this formula tested, or is the brand quoting its ingredient supplier?
- Comparison and endpoint: what was the control, and what changed—appearance ratings, surface measurements, or another outcome?
- Size and consistency of the change: are absolute results and variation reported, or only a selected photograph or best-case result?
- Duration: was the result assessed after use stopped?
A study of a formula containing several ingredients can be relevant to that formula. It does not automatically reveal how much one peptide contributed. Ingredient presence answers “is it included?”; it does not answer “how well does this product work?”
Safety and the boundary between an ingredient and a skincare product
A raw ingredient listing is not a ready-to-use skincare recommendation. Lotioncrafter explicitly warns against applying its Adifyline peptide solution directly to skin. This article does not provide recipes or instructions for using raw peptide powders or solutions.
I did not verify an ingredient-specific comprehensive safety assessment in the accessible sources reviewed. That prevents a blanket “safe for everyone” conclusion, but is not evidence that the ingredient is harmful. A product’s instructions and suitability remain separate questions from whether its marketing claims are persuasive.
For U.S. readers, the FDA substance identity record is particularly clear that having a UNII identifier does not imply regulatory review or approval. An identity listing should not be presented as FDA endorsement of a cream’s safety or volume claims. This regulatory context was checked on September 18, 2026 and is general information, not legal advice.
This article is for readers evaluating cosmetic ingredient claims. It provides general information, not medical advice or guidance on injections, treatment selection, or managing a skin condition. If you need help assessing a product for a medical concern or a reaction, consult a qualified healthcare professional.
FAQ
Is acetyl hexapeptide-38 the same as Adifyline?
They are related names, but context matters. Acetyl Hexapeptide-38 identifies the peptide ingredient; Adifyline is the commercial name associated with it. A supplied Adifyline solution also contains carriers, so it should not be treated as pure peptide.
Is it the same as acetyl hexapeptide-8?
No. Lubrizol lists Acetyl Hexapeptide-8 in its Argireline YOUth ingredient. The different ingredient names matter: findings or claims about number 8 cannot simply be transferred to number 38.
Does “hexapeptide” mean Botox-like?
No. The term describes a six-amino-acid peptide, not a proven action or a clinical result. Shared peptide length does not make different ingredients interchangeable, and it does not establish equivalence to a medical treatment.
Is a higher advertised percentage better?
A percentage alone cannot establish better results. First clarify whether it describes the branded ingredient solution or the peptide itself, then look for evidence relevant to the finished formula. The label’s number is not a substitute for a well-described comparison.
Have a question or an idea?
Get in touch with the Derma Dossier editorial team.
Contact us